BetterLife Pharma Announces Stock Option Grant
BetterLife Pharma (CSE: BETR) granted 300,000 stock options to a Scientific Advisory Board member, exercisable at C$0.25 per share. The options vest over 24 months and are part of the company's long-term incentive plan. BetterLife is developing BETR-001, a non-hallucinogenic LSD derivative, for chronic cluster headaches and migraines, with an IND application planned for Q1 2027.

